Business Wire

U.S. Businessman Issues Global, Multimillion Dollar (USD) Challenge for Innovative Alzheimer’s Solutions

Del

To expand the understanding and explanation of Alzheimer’s disease, United States businessman James Truchard has given a $5 million USD gift to The University of Texas at San Antonio (UTSA) College of Sciences to establish the Oskar Fischer Project. The initiative will engage the world’s brightest minds in a comprehensive literature review with the goal of synthesizing that information into one simple explanation for the cause of Alzheimer’s disease. The challenge was announced today during the Society for Neuroscience’s annual meeting, an international gathering of nearly 30,000 scientists taking place through Nov. 7 in the United States.

Truchard, retired president and chief executive officer of United States-based technology company National Instruments, conceptualized and established the Oskar Fischer Project to engage the world’s brightest minds. The challenge will award up to $4 million USD in Oskar Fischer Prizes, including a grand prize of $2 million, two second place prizes of $500,000 each and four third place prizes of $250,000 each. Collectively, the monetary awards are the world’s largest prizes of their kind.

Through personal research, Truchard, 75, was introduced to the work of Oskar Fischer (1876-1942), a Jewish pioneer in neuroscience who studied dementia at the same time as Alois Alzheimer. In 1900, Fischer began working at Charles University’s German University, based in Prague. His research led to the identification of senile plaques (then called neuritic plaques), the signature lesions of Alzheimer’s disease.

Fischer hypothesized that the plaques were associated with presbyophrenia, then characterized as a form of senile dementia marked by memory loss, memory distortions and disorientation. He published on 12 patients with plaques and tangles, protein strands that appear during Alzheimer’s disease, in 1907, the same year that Alzheimer published on one patient with early onset Alzheimer’s.

Fischer remained at the German University until he was removed in 1939. Two years later, he was sent to Theresienstadt in Terezín, a way station for Auschwitz and Treblinka. He died in 1942, unable to survive the harsh conditions of the concentration camp.

“A century has passed since Oskar Fischer’s seminal work, and tens of billions have been spent around the world on research and potential cures. Over 130,000 research papers have been published and yet no definitive explanation and cure for Alzheimer’s has been found,” said Truchard. “We need to look at Alzheimer’s as a big complex puzzle with a missing piece. We need a brilliant individual who can take all of the pieces and consider what each offers, and then develop one explanation that fits because it pulls all of the pieces together and makes the puzzle whole.”

According to the World Alzheimer Report 2018 by Alzheimer’s Disease International (ADI), an estimated 50 million people worldwide are living with dementia at a cost of $1 trillion to the global economy. That population is expected to more than triple by the year 2050, according to ADI, which also reports that the global ratio of publications on neurodegenerative disorders versus cancer is just one to 12.

“The Oskar Fischer Project will take a new systems approach to the research on Alzheimer’s, building on the work Oskar Fischer started over a century ago,” said George Perry, chief scientist of the UTSA Brain Health Consortium. “Jim Truchard’s generous gift will create an international forum to assess that work and bring forward an explanation that will advance society’s understanding of the disease.”

The University of Texas at San Antonio, a world leader in brain health research, will incubate the two-year challenge. In the UTSA Brain Health Consortium, 38 of the nation’s brightest scientists are engaged in research on brain mechanisms and therapeutics. The university’s researchers have expertise in neurodegenerative disease, brain circuits and electrical signaling, traumatic brain injury, regenerative medicine and stem cell therapies, medicinal chemistry and drug design, neuroinflammation, and psychology.

“Through Jim Truchard’s support, the Oskar Fischer Project will accelerate our shared mission of unraveling the mysteries of neurodegeneration through engagement with the smartest thinkers around the world,” said UTSA President Taylor Eighmy.

Truchard added, “I truly believe that Alzheimer’s disease is multifaceted; it’s about lifestyle, heredity and brain regression. It’s important to look at all possible solutions. This contest will bring together the world’s best minds to consider the entire story.”

UTSA will work closely with an interdisciplinary committee of outstanding scientists from Texas to award the Oskar Fischer Prizes. The call for proposals will open in February 2019 and will continue through the two-year term of the project.

About The University of Texas at San Antonio

The University of Texas at San Antonio (UTSA) is a public urban serving university specializing in health, cybersecurity, energy, sustainability, and human and social development. With more than 32,000 students, it is the largest university in the San Antonio metropolitan region. UTSA advances knowledge through research and discovery, teaching and learning, community engagement and public service. The university embraces multicultural traditions and serves as a center for intellectual and creative resources as well as a catalyst for socioeconomic development and the commercialization of intellectual property—for Texas, the nation and the world. Learn more online, on Facebook, on Twitter, on Instagram or on UTSA Today.

Contact information

UTSA
Joe Izbrand, 210-458-8754
University Communications and Marketing
Cell: 210-827-6525
joe.izbrand@utsa.edu

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Visa Strengthens Commitment to Growing Digital Payments in India16.11.2018 14:33Pressemelding

Visa (NYSE: V) today announced a minority investment in BillDesk, a leading platform for online payments and bill payments in India. Visa’s investment and collaboration will help BillDesk develop new product lines for its payments and loyalty businesses and also expand its footprint into other geographies. The investment will be subject to necessary statutory approvals and is expected to have no direct bearing on Visa’s existing Indian business. “As a leading payments player in India, BillDesk has been a long time business partner to Visa. Having worked with BillDesk’s founders over the years, the Visa leadership has been consistently impressed with their vision, market knowledge and execution capabilities, as well as alignment on values. This investment further reinforces our long-term commitment to India’s digital payments growth story,” said Asia Pacific regional president, Chris Clark. “We are truly excited by this investment from the world's largest global payment network, Visa. W

Guidewire Enhances PartnerConnect Consulting Program with Addition of Product and Regional Specializations16.11.2018 13:55Pressemelding

Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the addition of specializations to its PartnerConnect Consulting program. Specializations have been added to aid insurance companies in selecting the best partner to lead or staff their Guidewire projects. Guidewire unveiled new specializations, including two which have been successfully piloted earlier this year. “Our customers will now have more clarity and information as to which partners have the proven capabilities in their chosen product and region,” said Lisa Walsh, vice president, Alliances, Guidewire Software. “Adding these specializations will also allow us to have more insight into a partner’s performance and competencies.” To earn a specialization, partners need to demonstrate skills, knowledge, and competency in a specific Guidewire product or solution by certifying staff at multiple levels (specialist and professional) through Guidewire’

Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease16.11.2018 13:15Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for apalutamide, a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.2 The CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the use of apalutamide. The CHMP’s positive opinion is based on data from the pivotal SPARTAN Phase 3 clinical study which assessed the safety and efficacy of apalutamide versus placebo in patients with nmCRPC who have a rapidly rising prostate specific antigen (PSA) level despite receiving continuous androgen deprivation therapy (ADT). The SPARTAN clinical study showed that apalutamide, when added to ADT, significantly reduced the risk

Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease16.11.2018 12:57Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, lumacaftor/ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF for patients aged 2 to 5 years old who have two copies of the F508del mutation. “Cystic fibrosis is a chronic, progressive disease and it is important to treat early to ensure the best possible outcomes for patients,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. “Today’s announcement brings us one step cl

Dimension Data Global Delivery Centre (GDC) in Prague wins the ABSL 2018 Diamond Award for Business Innovation16.11.2018 08:00Pressemelding

Dimension Data, the USD 8 billion global technology integrator and managed services provider, today announced that its Global Delivery Centre (GDC) in Prague has won the 2018 ABSL Diamond award for Business Innovation. The main purpose of this centre is to provide innovative, global service delivery capabilities and deep technical expertise to support our clients. The ABSL Diamond awards recognise companies that implement innovative projects, enhancing their business and strengthening the position of the business services sector. Every year, the aim is to identify successful activities in this sector and promote best practices, ultimately encouraging and inspiring others to follow suit. The ABSL celebrates initiatives that push business services forward and stand out as exemplary projects. Bill Padfield, Group Chief Operating Officer for Transformation and Services at Dimension Data, said: “Winning another award for our Support Services is a fantastic achievement. This time the ABSL Di

FCC Grants LeoSat U.S. Market Access16.11.2018 06:00Pressemelding

LeoSat Enterprises, the dynamic young company which is launching a unique new data network comprised of a constellation of up to 108 low-earth-orbit communications satellites, has been awarded the authority by the U.S. Federal Communications Commission (FCC) to provide NGSO (non-geostationary satellite orbit) services in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005890/en/ LeoSat's Global Business Backbone in Space (Graphic: Business Wire) The increasing demand for business connectivity and with it, the need to move large quantities of data quickly and securely around the world, is fast outpacing the infrastructure in place to carry it. Existing networks are already carrying more than 1 Zeta Byte of traffic globally and this is set to grow exponentially. The FCC market access grant will allow LeoSat to address currently unmet demand for high-bandwidth, low-latency, high-security data transmissio